Literature DB >> 24398597

Prioritizing genomic applications for action by level of evidence: a horizon-scanning method.

W D Dotson1, M P Douglas2, K Kolor1, A C Stewart2, M S Bowen1, M Gwinn2, A Wulf3, H M Anders2, C Q Chang4, M Clyne5, T K Lam4, S D Schully4, M Marrone6, W G Feero7, M J Khoury8.   

Abstract

As evidence accumulates on the use of genomic tests and other health-related applications of genomic technologies, decision makers may increasingly seek support in identifying which applications have sufficiently robust evidence to suggest they might be considered for action. As an interim working process to provide such support, we developed a horizon-scanning method that assigns genomic applications to tiers defined by availability of synthesized evidence. We illustrate an application of the method to pharmacogenomics tests.

Entities:  

Mesh：

Year:  2014        PMID： 24398597      PMCID： PMC4689130          DOI： 10.1038/clpt.2013.226

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  54 in total

1.  Searching for the evidence using PubMed.

Authors:  Janis Glover
Journal:  Med Ref Serv Q       Date:  2002

2.  ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities.

Authors: 
Journal:  Obstet Gynecol       Date:  2007-01       Impact factor: 7.661

3.  Familial hypercholesterolaemia: summary of NICE guidance.

Authors:  Anthony S Wierzbicki; Steve E Humphries; Rubin Minhas
Journal:  BMJ       Date:  2008-08-27

4.  NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.

Authors:  Phillip G Febbo; Marc Ladanyi; Kenneth D Aldape; Angelo M De Marzo; M Elizabeth Hammond; Daniel F Hayes; A John Iafrate; R Kate Kelley; Guido Marcucci; Shuji Ogino; William Pao; Dennis C Sgroi; Marian L Birkeland
Journal:  J Natl Compr Canc Netw       Date:  2011-11       Impact factor: 11.908

Review 5.  Pharmacogenomics knowledge for personalized medicine.

Authors:  M Whirl-Carrillo; E M McDonagh; J M Hebert; L Gong; K Sangkuhl; C F Thorn; R B Altman; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2012-10       Impact factor: 6.875

6.  Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.

Authors:  S A Scott; K Sangkuhl; C M Stein; J-S Hulot; J L Mega; D M Roden; T E Klein; M S Sabatine; J A Johnson; A R Shuldiner
Journal:  Clin Pharmacol Ther       Date:  2013-05-22       Impact factor: 6.875

7.  Evidence-based classification of recommendations on use of genomic tests in clinical practice: dealing with insufficient evidence.

Authors:  Muin J Khoury; Ralph J Coates; James P Evans
Journal:  Genet Med       Date:  2010-11       Impact factor: 8.822

8.  A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice.

Authors:  David L Veenstra; Joshua A Roth; Louis P Garrison; Scott D Ramsey; Wylie Burke
Journal:  Genet Med       Date:  2010-11       Impact factor: 8.822

9.  Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin.

Authors:  David A Flockhart; Dennis O'Kane; Marc S Williams; Michael S Watson; David A Flockhart; Brian Gage; Roy Gandolfi; Richard King; Elaine Lyon; Robert Nussbaum; Dennis O'Kane; Kevin Schulman; David Veenstra; Marc S Williams; Michael S Watson
Journal:  Genet Med       Date:  2008-02       Impact factor: 8.822

10.  Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

Authors: 
Journal:  Genet Med       Date:  2013-02-21       Impact factor: 8.822
View more
  30 in total

1.  Moving the Needle on Action Around Evidence-Based Screening for Hereditary Conditions: Preparing State Chronic Disease Directors to Advance Precision Public Health.

Authors:  Amy Ponte; Samantha Greenberg; Karen Greendale; Laura Senier
Journal:  Public Health Rep       Date:  2019-03-21       Impact factor: 2.792

Review 2.  Precisely Where Are We Going? Charting the New Terrain of Precision Prevention.

Authors:  Karen M Meagher; Michelle L McGowan; Richard A Settersten; Jennifer R Fishman; Eric T Juengst
Journal:  Annu Rev Genomics Hum Genet       Date:  2017-04-24       Impact factor: 8.929

3.  A public health perspective on a national precision medicine cohort: balancing long-term knowledge generation with early health benefit.

Authors:  Muin J Khoury; James P Evans
Journal:  JAMA       Date:  2015-06-02       Impact factor: 56.272

Review 4.  Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions.

Authors:  Patricia A Deverka; Michael P Douglas; Kathryn A Phillips
Journal:  Value Health       Date:  2020-03-26       Impact factor: 5.725

Review 5.  Bridging the Gaps in Personalized Medicine Value Assessment: A Review of the Need for Outcome Metrics across Stakeholders and Scientific Disciplines.

Authors:  William S Bush; Jessica N Cooke Bailey; Mark F Beno; Dana C Crawford
Journal:  Public Health Genomics       Date:  2019-08-27       Impact factor: 2.000

6.  Challenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh in.

Authors:  Julia R Trosman; Christine B Weldon; R Kate Kelley; Kathryn A Phillips
Journal:  J Natl Compr Canc Netw       Date:  2015-03       Impact factor: 11.908

Review 7.  Precision Medicine at the University of Alabama at Birmingham: Laying the Foundational Processes Through Implementation of Genotype-Guided Antiplatelet Therapy.

Authors:  S Harada; Y Zhou; S Duncan; A R Armstead; G M Coshatt; C Dillon; B C Brott; J Willig; J A Alsip; W B Hillegass; N A Limdi
Journal:  Clin Pharmacol Ther       Date:  2017-06-01       Impact factor: 6.875

Review 8.  Strategic vision for improving human health at The Forefront of Genomics.

Authors:  Eric D Green; Chris Gunter; Leslie G Biesecker; Valentina Di Francesco; Carla L Easter; Elise A Feingold; Adam L Felsenfeld; David J Kaufman; Elaine A Ostrander; William J Pavan; Adam M Phillippy; Anastasia L Wise; Jyoti Gupta Dayal; Britny J Kish; Allison Mandich; Christopher R Wellington; Kris A Wetterstrand; Sarah A Bates; Darryl Leja; Susan Vasquez; William A Gahl; Bettie J Graham; Daniel L Kastner; Paul Liu; Laura Lyman Rodriguez; Benjamin D Solomon; Vence L Bonham; Lawrence C Brody; Carolyn M Hutter; Teri A Manolio
Journal:  Nature       Date:  2020-10-28       Impact factor: 49.962

9.  The Genetic Education for Men (GEM) Trial: Development of Web-Based Education for Untested Men in BRCA1/2-Positive Families.

Authors:  Beth N Peshkin; Mary Kate Ladd; Claudine Isaacs; Hannah Segal; Aryana Jacobs; Kathryn L Taylor; Kristi D Graves; Suzanne C O'Neill; Marc D Schwartz
Journal:  J Cancer Educ       Date:  2021-02       Impact factor: 2.037

Review 10.  From public health genomics to precision public health: a 20-year journey.

Authors:  Muin J Khoury; M Scott Bowen; Mindy Clyne; W David Dotson; Marta L Gwinn; Ridgely Fisk Green; Katherine Kolor; Juan L Rodriguez; Anja Wulf; Wei Yu
Journal:  Genet Med       Date:  2017-12-14       Impact factor: 8.822
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.